Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

A Long-Term Follow-up Study for Subjects Previously Treated with A Century Therapeutics Cellular Therapy Product Recruiting

2024-520222-11-00 Hematological or solid tumor malignancies or autoimmune 3 2026-03-03
TADalafil in early-stage Parkinson’s Disease (TAD-PD) Recruiting

2025-521819-39-00 Parkinson's disease 4 2026-03-02
First-in-Human Study of RO7812653 Recruiting

2025-522101-37-00 Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cogn 1 2026-02-17
A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy voluntee… Recruiting

2024-515935-31-04 Alzheimer´s disease 1 2026-02-16
A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting

2024-520097-36-00 Chronic inflammatory demyelinating polyneuropathy (CIDP 5 2026-01-07
Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke Recruiting

2025-522455-26-00 Acute Ischemic Stroke 9 2025-12-17
A PHASE II, SINGLE-CENTER, RANDOMIZED DOUBLE BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF THE COMBINED THERAPY OF EH-301 AND N-… Recruiting

2024-519857-13-00 Amyotrophic Lateral Sclerosis (ALS) 9 2025-11-25
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
Cabergoline for Episodic Migraine (PROTECT) Recruiting

2025-522323-10-00 Migraine 5 2025-11-12
An open-label study to assess the safety, efficacy, and cellular kinetics of YTB323 (rapcabtagene autoleucel) in Relapsingin Relapsing Multi… Recruiting

2024-512714-18-00 Relapsing Multiple Sclerosis 9 2025-11-11
A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting

2024-514974-39-00 Developmental and Epileptic Encephalopathies (DEEs) 5 2025-10-10
ASPIRING Recruiting

2024-516188-10-00 Intracerebral haemorrhage 6 2025-10-07
Evaluation of long-term safety in parkinsonian patients with intracerebroventricular administration of A-dopamine (anaerobic dopamine) - (DI… Recruiting

2025-522261-30-00 Parkinson disease 7 2025-10-01
Phase 1b/2a clinical trial to determine the safety, tolerability and efficacy of TZ-161 in Spinal Cord Injury Recruiting

2023-509207-33-01 Early acute spinal cord injury 9 2025-07-09
Restarting Early versus Later Anticoagulation for Chronic Subdural Hematoma with Atrial Fibrillation (RELACS) Recruiting

2025-521179-29-00 Chronic subdural hematoma 10 2025-07-06
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Refractory Partial Onset Epilepsy 5 2025-03-12
A prospective randomized open-label phase II clinical study evaluating the efficacy and safety of zoledronic acid addition to standard thera… Recruiting

2024-519446-67-00 Glioblastoma 4 2025-03-06
A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS) Recruiting

2024-512536-29-00 Amyotrophic Lateral Sclerosis (ALS) 4 2025-02-28
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Oral Ozanimod Compared to Oral Fingolimod in Children and Adolescents wi… Recruiting

2022-501332-42-00 Relapsing Remitting Multiple Sclerosis 5 2025-02-26
Cannabidiol in refractory childhood epilepsy, a personalized high-quality approach Recruiting

2023-507843-12-01 Refractory Epilepsy 5 2025-01-24
Synaptic density and tau pathology in Alzheimer’s disease Recruiting

2024-517636-22-00 Alzheimer's disease 4 2024-12-10
Concentration of ofatumumab in the breast milk of lactating women with relapsing forms of multiple sclerosis Recruiting

2023-505283-11-00 Relapsing forms of Multiple Sclerosis (RMS) 6 2024-12-10
A Study Evaluating the Patient Perspective of the Physical Impact of Multiple Sclerosis and Providing Continued Access to Treatment in Patie… Recruiting

2023-507633-21-01 Multiple Sclerosis 5 2024-12-09
Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla… Recruiting

2023-507746-83-00 Generalized Myasthenia Gravis 5 2024-11-27